Literature DB >> 35941224

Designing and executing prime editing experiments in mammalian cells.

Jordan L Doman1,2,3, Alexander A Sousa1,2,3, Peyton B Randolph1,2,3, Peter J Chen1,2,3, David R Liu4,5,6.   

Abstract

Prime editing (PE) is a precision gene editing technology that enables the programmable installation of substitutions, insertions and deletions in cells and animals without requiring double-strand DNA breaks (DSBs). The mechanism of PE makes it less dependent on cellular replication and endogenous DNA repair than homology-directed repair-based approaches, and its ability to precisely install edits without creating DSBs minimizes indels and other undesired outcomes. The capabilities of PE have also expanded since its original publication. Enhanced PE systems, PE4 and PE5, manipulate DNA repair pathways to increase PE efficiency and reduce indels. Other advances that improve PE efficiency include engineered pegRNAs (epegRNAs), which include a structured RNA motif to stabilize and protect pegRNA 3' ends, and the PEmax architecture, which improves editor expression and nuclear localization. New applications such as twin PE (twinPE) can precisely insert or delete hundreds of base pairs of DNA and can be used in tandem with recombinases to achieve gene-sized (>5 kb) insertions and inversions. Achieving optimal PE requires careful experimental design, and the large number of parameters that influence PE outcomes can be daunting. This protocol describes current best practices for conducting PE and twinPE experiments and describes the design and optimization of pegRNAs. We also offer guidelines for how to select the proper PE system (PE1 to PE5 and twinPE) for a given application. Finally, we provide detailed instructions on how to perform PE in mammalian cells. Compared with other procedures for editing human cells, PE offers greater precision and versatility, and can be completed within 2-4 weeks.
© 2022. Springer Nature Limited.

Entities:  

Year:  2022        PMID: 35941224     DOI: 10.1038/s41596-022-00724-4

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   17.021


  68 in total

1.  Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq.

Authors:  Giandomenico Turchiano; Geoffroy Andrieux; Julia Klermund; Georges Blattner; Valentina Pennucci; Melina El Gaz; Gianni Monaco; Sushmita Poddar; Claudio Mussolino; Tatjana I Cornu; Melanie Boerries; Toni Cathomen
Journal:  Cell Stem Cell       Date:  2021-02-23       Impact factor: 24.633

2.  CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.

Authors:  Haydar Frangoul; David Altshuler; M Domenica Cappellini; Yi-Shan Chen; Jennifer Domm; Brenda K Eustace; Juergen Foell; Josu de la Fuente; Stephan Grupp; Rupert Handgretinger; Tony W Ho; Antonis Kattamis; Andrew Kernytsky; Julie Lekstrom-Himes; Amanda M Li; Franco Locatelli; Markus Y Mapara; Mariane de Montalembert; Damiano Rondelli; Akshay Sharma; Sujit Sheth; Sandeep Soni; Martin H Steinberg; Donna Wall; Angela Yen; Selim Corbacioglu
Journal:  N Engl J Med       Date:  2020-12-05       Impact factor: 91.245

Review 3.  Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors.

Authors:  Andrew V Anzalone; Luke W Koblan; David R Liu
Journal:  Nat Biotechnol       Date:  2020-06-22       Impact factor: 54.908

4.  A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.

Authors:  Martin Jinek; Krzysztof Chylinski; Ines Fonfara; Michael Hauer; Jennifer A Doudna; Emmanuelle Charpentier
Journal:  Science       Date:  2012-06-28       Impact factor: 47.728

5.  Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements.

Authors:  Michael Kosicki; Kärt Tomberg; Allan Bradley
Journal:  Nat Biotechnol       Date:  2018-07-16       Impact factor: 54.908

6.  CRISPR-engineered T cells in patients with refractory cancer.

Authors:  Edward A Stadtmauer; Joseph A Fraietta; Simon F Lacey; Carl H June; Megan M Davis; Adam D Cohen; Kristy L Weber; Eric Lancaster; Patricia A Mangan; Irina Kulikovskaya; Minnal Gupta; Fang Chen; Lifeng Tian; Vanessa E Gonzalez; Jun Xu; In-Young Jung; J Joseph Melenhorst; Gabriela Plesa; Joanne Shea; Tina Matlawski; Amanda Cervini; Avery L Gaymon; Stephanie Desjardins; Anne Lamontagne; January Salas-Mckee; Andrew Fesnak; Donald L Siegel; Bruce L Levine; Julie K Jadlowsky; Regina M Young; Anne Chew; Wei-Ting Hwang; Elizabeth O Hexner; Beatriz M Carreno; Christopher L Nobles; Frederic D Bushman; Kevin R Parker; Yanyan Qi; Ansuman T Satpathy; Howard Y Chang; Yangbing Zhao
Journal:  Science       Date:  2020-02-06       Impact factor: 47.728

7.  UDiTaS™, a genome editing detection method for indels and genome rearrangements.

Authors:  Georgia Giannoukos; Dawn M Ciulla; Eugenio Marco; Hayat S Abdulkerim; Luis A Barrera; Anne Bothmer; Vidya Dhanapal; Sebastian W Gloskowski; Hariharan Jayaram; Morgan L Maeder; Maxwell N Skor; Tongyao Wang; Vic E Myer; Christopher J Wilson
Journal:  BMC Genomics       Date:  2018-03-21       Impact factor: 3.969

8.  Large-Fragment Deletions Induced by Cas9 Cleavage while Not in the BEs System.

Authors:  Yuning Song; Zhiquan Liu; Yuxin Zhang; Mao Chen; Tingting Sui; Liangxue Lai; Zhanjun Li
Journal:  Mol Ther Nucleic Acids       Date:  2020-06-25       Impact factor: 8.886

9.  Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors.

Authors:  Beau R Webber; Cara-Lin Lonetree; Mitchell G Kluesner; Matthew J Johnson; Emily J Pomeroy; Miechaleen D Diers; Walker S Lahr; Garrett M Draper; Nicholas J Slipek; Branden A Smeester; Klaus N Lovendahl; Amber N McElroy; Wendy R Gordon; Mark J Osborn; Branden S Moriarity
Journal:  Nat Commun       Date:  2019-11-19       Impact factor: 14.919

10.  CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.

Authors:  Julian D Gillmore; Ed Gane; Jorg Taubel; Justin Kao; Marianna Fontana; Michael L Maitland; Jessica Seitzer; Daniel O'Connell; Kathryn R Walsh; Kristy Wood; Jonathan Phillips; Yuanxin Xu; Adam Amaral; Adam P Boyd; Jeffrey E Cehelsky; Mark D McKee; Andrew Schiermeier; Olivier Harari; Andrew Murphy; Christos A Kyratsous; Brian Zambrowicz; Randy Soltys; David E Gutstein; John Leonard; Laura Sepp-Lorenzino; David Lebwohl
Journal:  N Engl J Med       Date:  2021-06-26       Impact factor: 91.245

View more
  1 in total

1.  Marker-free co-selection for successive rounds of prime editing in human cells.

Authors:  Sébastien Levesque; Diana Mayorga; Jean-Philippe Fiset; Claudia Goupil; Alexis Duringer; Andréanne Loiselle; Eva Bouchard; Daniel Agudelo; Yannick Doyon
Journal:  Nat Commun       Date:  2022-10-07       Impact factor: 17.694

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.